-
Nu.Q® Technology
Our technology detects characteristic epigenetic changes in nucleosomes that occur from the earliest stages of cancer, sepsis and other diseases.
-
- Our Tests
- Human Health
-
Nu.Q® NETs
Nu.Q® NETs is a groundbreaking CE-marked diagnostic solution that clinicians can use to detect NETosis.
-
Nu.Q® Discover
Buy our Nu.Q® Discover H3.1 Research Use Only Assay
- Animal Health
-
Nu.Q® Vet Cancer Test
Nu.Q® Vet Cancer Test detects 76% of systemic cancers at 97% specificity.
Utility of Monitoring H3.1 Plasma Concentrations as a Surrogate of Treatment Response and Remission in Dogs with Cancer
- Share
- Tweet
- Share on Facebook
- Share
Poster titled: ‘Utility of Monitoring H3.1 Plasma Concentrations as a Surrogate of Treatment Response and Remission in Dogs with Cancer’.
Presented at: World Veterinary Cancer Congress 2024, Tokyo 2024
Dr Heather Wilson-Robles et al
- Share
- Tweet
- Share on Facebook
- Share
Subscribe for Volition product updates.
Or, click here for Investor Updates and press releases.
"*" indicates required fields